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Abstract
Purpose—The purpose of the current study was to assess the penetrance of NRXN1 deletions.
Methods—We compared the prevalence and genomic extent of NRXN1 deletions identified 
among 19,263 clinically referred cases to that of 15,264 controls. The burden of additional 
clinically relevant CNVs was used as a proxy to estimate the relative penetrance of NRXN1 
deletions.
Results—We identified 41 (0.21%) previously unreported exonic NRXN1 deletions ascertained 
for developmental delay/intellectual disability, significantly greater than in controls [OR=8.14 
(95% CI 2.91–22.72), p< 0.0001)]. Ten (22.7%) of these had a second clinically relevant CNV. 
Subjects with a deletion near the 3′ end of NRXN1 were significantly more likely to have a 
second rare CNV than subjects with a 5′ NRXN1 deletion [OR=7.47 (95% CI 2.36–23.61), 
p=0.0006]. The prevalence of intronic NRXN1 deletions was not statistically different between 
cases and controls (p=0.618). The majority (63.2%) of intronic NRXN1 deletion cases had a 
second rare CNV, a two-fold greater prevalence than for exonic NRXN1 deletion cases 
(p=0.0035).
Conclusions—The results support the importance of exons near the 5′ end of NRXN1 in the 
expression of neurodevelopmental disorders. Intronic NRXN1 deletions do not appear to 
substantially increase the risk for clinical phenotypes.
Keywords
NRXN1; copy number variation; genotype-phenotype; variable expression; penetrance
INTRODUCTION
Neurexins are a group of highly polymorphic presynaptic cell adhesion molecules that 
primarily bind to neuroligins.1 The three neurexin genes (NRXN1, NRXN2 and NRXN3) 
are highly conserved and undergo extensive alternative splicing2 to produce thousands of 
isoforms that appear to be both spatially and temporally regulated.3,4 The two main isoforms 
for each neurexin gene, the longer NRXN-α and the shorter NRXN-β, are transcribed from 
two independent promoter regions and give rise to proteins with similar C-terminal regions 
but different N-terminal ectodomains.5 The NRXN-α and NRXN-β isoforms both bind to 
postsynaptic neuroligins and leucine-rich repeat transmembrane proteins, however with 
varying degrees of affinity.1,6,7 NRXN-α also binds to dystroglycan and cerebellin.8,9 
NRXN1 (OMIM 600565) is the largest neurexin gene (comprising about 1.1 Mb of genetic 
sequence)2 and the one most implicated as a top candidate gene for neurodevelopmental and 
neuropsychiatric conditions (Figure 1).10
Rare exonic deletions overlapping NRXN1 on chromosome 2p16 were first identified in 
individuals with autism spectrum disorder (ASD)11,12 and developmental delay/intellectual 
disability (DD/ID).13 Subsequently, such deletions have been identified in individuals with 
various neurodevelopmental and neuropsychiatric disorders.14–20 A few exonic NRXN1 
deletions have been identified in controls and the majority of transmitting parents are 
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reported to be only mildly affected or clinically unaffected.10,14 Understanding the factors 
that contribute to this incomplete penetrance is a key goal for clinical genetics.
Exonic NRXN1 deletions are non-recurrent and are found across the entire length of this 
large gene.2,10,21,22 There is conflicting evidence to suggest that the deletion extent may 
underlie the NRXN1 phenotypic heterogeneity.10,21 A recent study found that individuals 
with ASD are significantly more likely to harbor a rare de novo mutation in exons that are 
under purifying selection (called “critical exons”) than their siblings,23 suggesting that 
certain sequences within NRXN1 may be more important for clinical expression than others. 
Also, there is accumulating evidence to suggest that non-coding regions of the genome, 
including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), play an important 
role in the aetiology of neurodevelopmental disorders.24,25 Deletions upstream and within 
introns of NRXN1 have been identified in disease cases;14,22,26 however the pathogenicity 
of these deletions remains unclear.
As the use of genome-wide microarray technology in the prenatal setting increases,27 so too 
does the need for improved understanding of the genetic factors that impact the penetrance 
of NRXN1 deletions to inform genetic counselling and anticipatory care. We used a large 
(n=19,263) clinically ascertained cohort from southern Ontario, Canada and 15,264 
population-based controls to investigate the penetrance of NRXN1 deletions. CNV data 
from high resolution genome-wide microarrays allowed systematic evaluation of the burden 
of secondary CNVs that we used as a proxy to estimate the relative penetrance of exonic and 
intronic NRXN1 deletions.
MATERIALS AND METHODS
Exonic NRXN1 deletions: clinical cohorts examined
We searched three Province of Ontario accredited clinical cytogenetics laboratory databases 
for cases with exonic NRXN1 deletions. These included subjects submitted for clinical 
microarray testing before January 2015 at the Hospital for Sick Children (n=11,727), 
Trillium Health Partners (n=6,022), and Hamilton Health Sciences (n=1,514), all located in 
southern Ontario, Canada. All three laboratories are provincially funded to provide clinical 
constitutional microarray testing for individuals with DD/ID, ASD and/or multiple 
congenital anomalies (MCA). The NRXN1 deletion cases identified in this study therefore 
have a strong ascertainment bias for these conditions. Participating physicians completed a 
detailed clinical checklist (Table S1) for each exonic NRXN1 deletion case based on their 
own clinical assessment and lifetime chart reviews, where available. For cases without 
clinical checklist data, ascertainment and demographic data were collected from laboratory 
requisition forms. We also included three additional cases with an exonic NRXN1 deletion 
(P30, P34 and P35; Figure 1) detected by other clinical laboratories in order to increase the 
overall number of cases with genome-wide CNV data. These cases were not included in 
NRXN1 deletion prevalence calculations for the catchment area.
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Molecular methods and validation
All exonic NRXN1 deletions (chr2:50,145,643–51,259,674; hg19) in cases were identified 
by one of three microarray platforms, the Affymetrix CytoScan® HD Array, the Oxford 
Gene Technology (OGT) 4×180 CytoSure Oligonucleotide array or the Illumina (formally 
BlueGnome) 4x180K CytoChip ISCA array. The OGT and Illumina arrays are similar in 
design with approximately 200–250 oligonucleotide probes (average probe spacing 5.5–7.6 
kb) distributed across the NRXN1 gene, allowing for a minimum deletion detection of 10 kb. 
The CytoScan® HD array has approximately 650 oligonucleotide probes distributed across 
NRXN1, with similar minimum deletion detection capabilities. All genomic coordinates are 
given using the Genome Reference Consortium February 2009 build of the human genome 
(GRCh37/hg 19). Genomic coordinates for the 22 NRXN1 exons (α1 transcript; 
NM_004801.4) were obtained from the NCBI RefSeq database. Exonic NRXN1 deletions 
≥100 kb were confirmed using fluorescence in situ hybridization (FISH). Smaller deletions 
were confirmed by qPCR or by a second microarray.
Additional clinically relevant CNVs as a proxy for calculating the relative penetrance of 
NRXN1 deletions
All three clinical laboratories classified a deletion overlapping any one or more of the 22 
NRXN1 exons (NM_004801.4) as pathogenic. Therefore, we used the presence of a second 
clinically relevant CNV as a proxy for estimating the relative penetrance of the NRXN1 
deletions. As previously shown,28 CNVs with high penetrance (i.e., not identified in control 
cohorts) are less likely to harbor a second independent large rare CNV.28 The high-
resolution genome-wide CNV data from each NRXN1 deletion case was investigated for the 
presence of a second CNV that may be clinically relevant. The clinical interpretation of 
these second CNVs as pathogenic, likely pathogenic, or as a variant of unknown significance 
(VUS) was provided by one of the three experienced clinical laboratory directors using the 
American College of Medical Genetics guidelines for CNV interpretation.29 Other clinically 
relevant variants detected by different laboratory tests were not included in our statistical 
analyses.
Phenotypic data
The clinical checklist completed for each exonic NRXN1 deletion case is presented in Table 
S1. Briefly, data were collected on ascertainment features, demographic variables (age, sex), 
growth parameters (height, weight, head circumference) and growth abnormalities, 
dysmorphic features, and lifetime developmental, psychiatric, medical, and family history 
based on clinical assessment and/or lifetime medical chart reviews. If completed, previous 
clinical genetic testing results were provided. Where known, data on parental phenotypes 
were collected.
Control cohorts
To examine the prevalence of exonic and intronic NRXN1 deletions in the general 
population we used 15,264 controls with CNV data available from high-resolution genome-
wide arrays (Table S3). These controls were analyzed on several different array platforms 
with variable probe spacing. Therefore, similar to previous studies,30 we only included 
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exonic and intronic deletions identified by a minimum of two of three CNV calling 
algorithms (iPattern, PennCNV, ChAS), spanning 5 consecutive array probes and over 10 kb 
in size. Over 90% of CNVs called using this method validate using other laboratory 
methods.30
Intronic NRXN1 deletions
Trillium Health Partners was the only clinical laboratory that systematically recorded 
intronic NRXN1 deletions. These clinical cases (n=6,022) were analyzed using the Illumina 
4x180K CytoChip ISCA array which had even probe spacing across introns. We used two 
strategies to assess the pathogenicity of intronic NRXN1 deletions. First, we compared the 
prevalence of intronic NRXN1 deletions between clinically referred cases and the 15,254 
population-based controls described above. Second, we assessed the prevalence of secondary 
CNVs among the intronic NRXN1 deletion cases and compared this to the prevalence for 
exonic NRXN1 deletion cases.
Statistical analyses
Statistical analyses were performed using SAS software (version 9.2; SAS Institute, Cary, 
NC). For categorical data we used χ2 or Fishers exact test, where appropriate. For 
continuous data we used Welch’s t-test. All analyses were two tailed, with statistical 
significance defined as p<0.05. Odds ratios (OR) and 95% confidence intervals were used to 
assess the prevalence of secondary CNVs between deletions overlapping one or more of 
exons 1–4 and those overlapping exons ≥5 and the association between the NRXN1 
deletions (exonic and intronic) ascertained from the clinical diagnostic population compared 
to controls.
RESULTS
Prevalence of exonic NRXN1 deletions in cases and controls
As of January 2015, a total of 19,263 individuals were submitted for clinical microarray 
testing across the three participating cytogenetics laboratories. There were 41 (0.21%) 
unrelated, previously unpublished, probands identified to have deletions overlapping one or 
more NRXN1 exons (Figure 1). The prevalence of exonic NRXN1 deletions for the 
individual laboratories was 0.33%, 0.26%, and 0.14% (Table S4). The prevalence of exonic 
NRXN1 deletions was significantly greater in cases compared to 15,264 controls [OR=8.14 
(95% CI 2.91–22.72), p< 0.0001)] (Table S3).
Exonic NRXN1 deletions
Genomic coordinates for all 44 exonic NRXN1 deletions, including three additional cases 
with exonic NRXN1 deletions from laboratories outside the catchment area, are represented 
in Figure 1. All were non-recurrent, with sizes ranging from 29 kb to 806 kb (median=244 
kb). The majority of the deletions (n=32; 72.7%) overlapped at least one or more of exons 
1–4 (referred to as a 5′ NRXN1 deletion hereafter). Ten (22.7%) deletions overlapped exons 
≥5 (hereafter termed 3′ NRXN1 deletions). Two deletions (P28 and P30; Figure 1) that 
overlapped both the 5′ and 3′ end of NRXN1 were excluded from analyses comparing 5′ 
and 3′ NRXN1 deletions but not the descriptive statistics. This categorization of exons has 
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been used in previous publications.10,21 The 5′ NRXN1 deletions (median size=242 kb) 
were significantly larger than the 3′ NRXN1 deletions (median size=83 kb), [t(18.5)=2.55, 
p=0.019].
The 44 exonic NRXN1 deletions were inherited (11 maternal, 5 paternal) in 16 (64.0%), de 
novo in nine (36.0%) and unknown in 19 subjects. Of these, 5′ NRXN1 deletions were 
inherited in thirteen (61.9%) and de novo in 8 (38.1%) subjects; 3′ NRXN1 deletions were 
inherited in 3 (75.0%) and de novo in 1 (25.0%) subject. Of the 11 transmitting mothers, 
four were identified as clinically affected: three with mild ID and one with anxiety and 
depression. Clinical outcomes for the remaining seven transmitting mothers and five 
transmitting fathers were unknown.
Genome-wide prevalence of additional clinically relevant CNVs
Clinical microarray testing identified 10 (22.7%) exonic NRXN1 deletion cases with one or 
more additional clinically relevant CNV (n=14), ranging in size from 38 kb to whole 
chromosomal anomalies (Table 1). The prevalence of males (n=7/28; 25.0%) with a 
secondary CNV was similar to that of females (n=3/16; 18.8%). Twelve (85.7%) of these 
CNVs were classified as VUS and two as pathogenic (Table 1). The two pathogenic CNVs 
were de novo, two of the VUS were paternally inherited and the remaining 10 additional 
VUS were of unknown inheritance. The prevalence of these secondary CNVs was 
significantly higher in subjects with a 3′ NRXN1 deletion (n=7/10; 70.0%) compared to 
subjects with a 5′ NRXN1 deletion (n=3/32; 9.4%) [OR=7.47 (95% CI 2.36–23.61), 
p=0.0006] (Figure 1). Eleven (78.6%) of the fourteen secondary CNVs overlapped one or 
more genes known to be involved in central nervous system function (Table 1).
Clinical characteristics of exonic NRXN1 deletion cases
Completed clinical checklists were returned for 21 (47.7%) exonic NRXN1 deletion cases 
by referring physicians, with basic ascertainment and demographic data available for the 
other 23 cases (Table S2). As expected given the criteria for microarray testing, all of the 44 
probands (16 female, 28 male) with exonic NRXN1 deletions were ascertained for DD/ID. 
Thirty-five (79.5%) were children (median 5.2, range 1–6 years) and nine (20.5%) were 
adults (median 32.0, range 21–59 years).
There were 20 (45.5%) subjects who met diagnostic criteria for another (i.e., additional to 
DD/ID) neurodevelopmental and/or neuropsychiatric condition, often referred to as ‘dual 
diagnosis’. Including multiple features per subject, the prevalence of these conditions was: 
ASD or pervasive developmental disorder (n=14; 31.8%), epilepsy/seizures (n=6; 13.6%), 
ADHD (n=4; 9.1%), anxiety (n=3; 6.8%), Tourette’s syndrome (n=2; 4.5%) and tardive 
dyskinesia secondary to antipsychotic treatment in two adults with schizophrenia (n=2; 
4.5%). There was no significant difference in the prevalence of dual diagnosis, seizures/
epilepsy or macrocephaly between subjects with a 5′ NRXN1 deletion compared to subjects 
with a 3′ NRXN1 deletion (data not shown).
In contrast to the prominent neurodevelopmental phenotype, congenital anomalies were 
identified in only four (9.1%) cases: two with tetralogy of Fallot (TOF), one of whom also 
had a tracheoesophageal fistula and imperforate anus, a third with cryptorchidism, and a 
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fourth with a small atrial septal defect. All four of these subjects had a 5′ NRXN1 deletion 
and none were identified to have a rare second CNV. However, one TOF case was identified 
to have a RAF1 sequence mutation causing Noonan syndrome (OMIM 611553).
Eleven (25.0%) cases had additional clinical genetic testing that was found to be normal, 
including karyotype, fragile X syndrome, 22q11.2 deletion syndrome, Prader-Willi 
syndrome, muscular dystrophy gene panel and a gene panel for progressive myoclonic 
epilepsy. Two long contiguous stretches of homozygosity on chromosome 14 (identified on 
follow-up to be maternal uniparental disomy of chromosome 14) were identified in a single 
subject (P14; Figure 1).
Intronic NRXN1 deletions
We identified 19 of 6,022 (0.32%) cases submitted for clinical microarray testing and 55 of 
15,264 (0.36%) controls to have an intronic NRXN1 deletion (Figure 1). In contrast to the 
prevalence of exonic NRXN1 deletions identified in this laboratory (0.33% [OR 12.67 (95% 
CI 4.33–37.08), p<0.0001], there was no significant difference in the prevalence of intronic 
NRXN1 deletions between cases and controls [OR 0.88 (95% CI 0.52–1.48), p=0.618)]. 
These intronic NRXN1 deletions ranged in size from 11 kb to 134 kb (median=38 kb), 
significantly smaller than the 44 exonic deletions (p<0.0001). The majority (n=14; 73.7%) 
of the intronic deletions were located in the large intron 5 (Figure 1). Inheritance data are 
limited as most of the intronic deletions were not included in clinical reports; one case had 
follow-up and was found to be paternal in origin. Several of the intronic deletions were 
recurrent, including a 70.6 kb deletion in intron 5 and an 11.1 kb deletion in intron 18. 
Twelve (63.2%) of the 19 intronic NRXN1 deletion cases had a second reportable CNV on 
clinical microarray (Table 2), a significantly greater prevalence than for the exonic NRXN1 
deletion cases [OR=2.59 (95% CI 1.37–4.91); p=0.004].
Of these 19 (11 female, 8 male) unrelated cases with intronic NRXN1 deletions, 17 (89.5%) 
were children (median=5.0, range 0.5–10 years) and two were adults (Table S2). Sixteen 
(84.2%) were ascertained for DD/ID and/or ASD and three (6.8%) for MCA (n=1), CHD 
(n=1) and absent radius/thumb. Of the 16 cases with DD and/or ASD, ten (62.5%) had a 
second rare CNV that overlapped one or more genes involved in central nervous system 
function (Table 2).
DISCUSSION
This is the largest study characterizing exonic and intronic NRXN1 deletions to date. Our 
aim was to use data from a large clinical population-based sample to systematically 
investigate factors affecting the penetrance of deletions overlapping this large gene. In 
addition to confirming the predominantly neuropsychiatric phenotypic expression of 
pathogenic CNVs overlapping NRXN1, novel results support the importance of the genomic 
extent of these deletions, including the particular region involved and overlapped exons.
Penetrance of exonic NRXN1 deletions
We report on 44 novel exonic NRXN1 deletion cases ascertained for DD/ID (Table S2). We 
assessed penetrance using multiple factors, both those used previously (prevalence in cases 
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versus controls and the ratio of de novo versus inherited deletions) and those novel to this 
study (prevalence of secondary CNVs and classification as pathogenic or VUS). We found 
that the 0.21% prevalence of exonic NRXN1 deletions in this clinical population was over 8-
fold greater than in controls and that 34% of these deletions were identified to be de novo, 
supporting the relatively high penetrance of these deletions for clinically important 
phenotypes. About one in every four cases with an exonic NRXN1 deletion had one or more 
other rare CNVs reported on clinical microarray (Table 1). Their distribution amongst the 
cases indicated a relatively lower penetrance of 3′ NRXN1 deletions.
The effect of genomic position on penetrance of exonic NRXN1 deletions
Similar to previous studies,10,21,22,31 the majority of the exonic NRXN1 deletions identified 
in clinical cases overlapped the promoter and the first few exons of the NRXN1-α transcript. 
For subjects with deletions overlapping the 3′ end of NRXN1 there was an over 7-fold 
increased likelihood of having a second clinically relevant CNV compared to subjects with a 
5′ NRXN1 deletion (Figure 1). Further, none of the additional rare CNVs identified in the 
5′ NRXN1 deletion subjects were classified as pathogenic, demonstrating the relative 
importance of 5′ NRXN1 deletions over 3′ NRXN1 deletions for the expression of clinical 
phenotypes.
A potential explanation for the higher penetrance of 5′ NRXN1 deletions may be that these 
deletions directly overlap or indirectly influence the lncRNA AK127244 that is adjacent to 
the promoter of NRXN1-α (Figure 1). There is accumulating evidence to suggest that 
AK127244 may play a role in the etiology of neuropsychiatric disorders.26,32,33 This 
includes the identification of two deletions that overlap this lncRNA (and not NRXN1) in a 
child with borderline IQ and early onset schizophrenia.32 A recent report also described five 
ASD cases with deletions overlapping AK127244.26 The biological function of AK127244 
has yet to be elucidated. However, a significant proportion of lncRNAs are expressed in the 
brain and have important roles in neurodevelopmental processes.34
There was little evidence that additional phenotypic features were indicators of higher 
penetrance in individuals with exonic NRXN1 deletions in this study. This could be due in 
part to a high phenotypic floor effect present in clinically recruited subjects. It is interesting 
to note that the two adults with comorbid ID and schizophrenia in this study had deletions 
overlapping the 5′ end of NRXN1. Similarly, in the largest study of NRXN1 deletions in 
schizophrenia to date there were 10 exonic NRXN1 deletions identified, the majority of 
which overlapped the 5′ end of NRXN1.14 Also, two cases from this study had a deletion 
overlapping AK127244 but not NRXN1,14 providing support for the possible role of this 
lncRNA in the etiology of schizophrenia.
In contrast to our findings supporting the reduced penetrance of 3′ NRXN1 deletions, the 
limited number of these deletions reported in the literature had previously led to the 
hypothesis that they are associated with severe phenotypes, including prenatal lethality.31 To 
further investigate if deletions overlapping the 3′ end of NRXN1 are associated with 
prenatal lethality we examined ten studies of miscarriages and/or stillbirths (see refs 6 and 
17–26 in Rosenfeld et al.)35 for rare CNVs overlapping NRXN1. Among >900 products of 
conception there was only one paternally inherited 95 kb deletion overlapping NRXN1-α 
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(exons 2–4) identified.35 We also identified one deletion overlapping the NRXN1-β 
promoter among 15,254 controls. These data provide further support for the increased 
penetrance of 5′ relative to 3′ NRXN1 deletions.
Interpretation of intronic NRXN1 deletions
We identified 19 novel cases with an intronic NRXN1 deletion, 16 with DD/ID and/or ASD 
and three with a congenital anomaly. Our group used two strategies to assess the penetrance 
of intronic NRXN1 deletions. First, we compared the prevalence of intronic NRXN1 
deletions between cases and population-based controls and detected no significant 
difference. Indeed, 18 of the 19 intronic NRXN1 deletions identified in cases had 
breakpoints similar to those seen in controls (Figure 1). Second, we determined that intronic 
NRXN1 deletion cases were two-fold more likely to harbour a second clinically relevant 
CNV compared to exonic NRXN1 deletion cases. Therefore, intronic NRXN1 deletions 
appear unlikely to substantially increase the risk for a neurodevelopmental disorder and/or 
MCA.
However, seven (36.8%) of the intronic NRXN1 deletion cases, each with severe phenotypes 
had no additional rare CNV reported on clinical microarray. One of these seven NRXN1 
deletions overlapped intron 9 (Case I16; Figure 1), which had no corresponding deletion 
identified in controls. Using the VISTA enhancer browser (https://enhancer.lbl.gov)36 we 
identified a known enhancer element (hs1348) located 37 kb upstream of the intron 9 
deletion, which if perturbed could potentially alter the transcriptional levels of NRXN1 and 
thus increase the penetrance of this deletion.
Advantages and limitations
There are several advantages to this study. We used data from three clinical laboratories to 
compile the largest cohort of clinically referred individuals with exonic and intronic NRXN1 
deletions assembled to date. Our systematic approach to the detection and interpretation of 
additional rare CNVs allowed us to use the burden of these secondary CNVs as a proxy for 
determining the relative penetrance of NRXN1 deletions. We employed robust methods for 
CNV detection, to evaluate the prevalence of intronic NRXN1 deletions in cases and 
controls which had previously been ignored due to the use of different CNV calling 
algorithms and reporting practices across clinical laboratories.
A limitation of this study is that the prevalence of individual clinical features would 
necessarily be influenced by the ascertainment bias inherent in clinically referred cases. This 
tends to overestimate DD/ID and underestimate other features. The prevalence of NRXN1 
deletions was about an order of magnitude different between each clinical laboratory, 
reaching statistical significance between the Hospital for Sick Children (0.14%) and Trillium 
Health Partners (0.33%) [OR 2.29 (95% CI 1.19–4.39), p=0.012)] (Table S3). This may be 
due to differences in indications for referral, with the Hospital for Sick Children and 
Hamilton Health Sciences servicing children with the most severe and intractable 
neurological disorders from this catchment area. Given that some NRXN1 deletions are 
identified in control subjects,14,31 it is possible that the prevalence of these deletions is 
highest at Trillium Health Partners since it is a community-based hospital that services 
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individuals with comparatively milder clinical phenotypes. The resolution of the microarrays 
used to define the NRXN1 deletion breakpoints and detect genome-wide structural variants 
limited us to those >10 kb that could influence phenotypic expression.
Only one control cohort (OPGP; Table S3) was systematically screened for 
neurodevelopmental and/or neuropsychiatric conditions. Control subjects with NRXN1 
exonic or intronic deletions may thus have had mild and/or subclinical symptoms. This 
could have reduced the effect size of the case-control results. We did not have access to the 
individual SNP data for the NRXN1 deletion cases or the controls and as a result were 
unable to genetically confirm that each individual was unrelated to any other. However, 
given that none of the exonic NRXN1 deletions identified in cases or controls had similar 
breakpoints it is unlikely that these individuals were related. Further, only two of the eight 
control cohorts (Table S3) were ascertained from the same catchment area as our cases and 
they included adults only. This makes it unlikely that the intronic NRXN1 deletion cases 
(89% children) were the same individuals as those among the controls.
Future directions
The major challenge moving forward will be to determine how genetic and non-genetic 
factors converge to explain the variable expression and incomplete penetrance of exonic and 
intronic NRXN1 deletions. Examination of the genes overlapped by additional rare CNVs as 
well as applying next generation sequencing to detect variants within the coding and non-
coding regions of the genome in subjects with a NRXN1 deletion may serve as a key step 
towards identifying novel pathways to disease expression. Interestingly, none of the second 
rare CNVs identified in this study have been previously reported in combination with an 
exonic NRXN1 deletion,10,21,22,31 suggesting that a large NRXN1 deletion consortium may 
be required to compile enough cases to identify novel biological patterns among the 
additional variants.
Conclusions
The expression of exonic NRXN1 deletions appears to be primarily neuropsychiatric, with 
DD/ID often comorbid with another neuropsychiatric condition. The results of this study 
suggest that deletions near the 5′ end of NRXN1 have higher penetrance, potentially related 
to perturbation of the lncRNA AK127244 located adjacent to the NRXN1-α promoter. 
Subjects with a 3′ NRXN1 deletion had a 7-fold increased likelihood of having a second 
rare CNV detected by clinical microarray, supporting reduced penetrance for these deletions. 
There is insufficient evidence as yet to suggest that all intronic NRXN1 deletions are benign.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Novel exonic and intronic NRXN1 deletions identified in cases and controls
The image was modified from the Database of Genomic variants (http://dgv.tcag.ca), NCBI 
Build 37 (hg 19).37,38 The two primary NRXN1 transcripts (α1 and β1) are shown in pink; 
other transcripts are not included. The long non-coding RNA (lnRNA) AK127244 is shown 
in green. Each of the 22 exons is identified by a number according to the NM_004801.4 
transcript. The five splice site (SS 1-5) locations are represented above the NRXN1-α 
transcript. The hollow pink box denoted by a P adjacent to each transcript represents the α 
and β promoter, respectively. All exonic and intronic deletions (chr2: 50,145,643–
51,259,647; hg 19) are represented by solid red and yellow bars, respectively. Deletions with 
a black grid are subjects that were identified to have a second CNV of potential clinical 
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relevance. Inheritance status of the NRXN1 deletion is represented in brackets following the 
patient ID number (d.n., de novo; mat, maternal inheritance; pat, paternal inheritance; blank, 
unknown). P28 and P30 overlap both the 5′ and 3′ ends of NRXN1 and were not included 
in statistical analyses. P14 and P32 were identified to have maternal uniparental disomy of 
chromosome 14 and a RAF 1 mutation, respectively. The light blue box designates subjects 
with deletions overlapping exons ≥5 (3′ deletion). Case numbers were kept consistent 
throughout the manuscript, tables and supplemental documents. Cases P30, P34 and P35 
were obtained from other laboratories and are represented in bold font.
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